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Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited 
cardiac disorder characterised by structural and functional abnormalities of the right ventricle 
with or without left ventricular involvement. In 1994, Task Force criteria (TFC) were proposed 
for the diagnosis of ARVC and were found to be highly specific but lacked sensitivity. In 2010, 
revised TFC were proposed to increase sensitivity and facilitate diagnosis in those with subtle 
phenotypes. 
 
Purpose:  Many participants of ARVC registries have been enrolled using the 1994 TFC and 
not re-analysed using the 2010 TFC. We retrospectively compared the utility of both TFC for 
the diagnosis of mutation-positive probands in the IMHOTEP (The African Cardiomyopathy 
and Myocarditis Registry Program) study with the aim of identifying diagnostic changes that 
may have clinical impact.  
 
Method: 162 participants with the suspicion of ARVC were referred between May 2003 and 
May 2018 to our ARVC registry. 150 cases were reviewed using the same ECG and imaging 
data to fulfil both TFC, and were re-classified by a diagnostic panel at Groote Schuur Hospital, 
Cape Town. 
 
Results: Sixty-eight participants were diagnosed with ARVC by the diagnostic panel and 
included into the registry; 14/68 participants with ARVC were found to be mutation-positive. 
Eighty-two participants were found to have an alternative diagnosis or insufficient criteria and 
were excluded from the ARVC registry. Mutation-positive probands presented at a significantly 
younger age compared to the mutation-negative group (29 ± 14 years versus 39 ± 13 years, 
p=0.009), suggesting an earlier onset of ARVC. Common reasons for presentation in the 
mutation-positive cohort included palpitations (79%) and presyncope (64%), with 
Page 11 of 78 
 
approximately twice the number of participants presenting with sustained ventricular 
tachycardia (VT) compared to mutation-negative participants (79% versus 47%, p=0.036).  
The diagnostic yield of the 2010 versus 1994 TFC (n=68) revealed more participants with a 
definite diagnosis, and less featuring in possible and no criteria categories. A 67% (n=8) 
change in diagnosis from 1994 borderline to 2010 definite, and an 88% (n=7) change from 
1994 possible to 2010 borderline, were observed. Mutation-positive participants had a higher 
yield for definite ARVC when compared to mutation-negative participants. We subsequently 
analysed the contribution of each diagnostic modality at fulfilling TFC in our mutation-positive 
definite participants and found CMR contribution statistically significant, p=0.021. 
 
Conclusion: Our study found that mutation-positive probands were found to be younger, 
more likely to present with sustained VT, fulfilled a significantly larger number of major 2010 
TFC than mutation-negative probands, and that the 2010 TFC for structural and repolarisation 
abnormalities were more useful in diagnosing ARVC compared to 1994 TFC. We found a 
significant evolution in classification between both TFC, suggesting that re-classification of 
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Chapter 1 - Literature review 
 
1.1      Introduction  
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease 
characterised by structural and functional abnormalities of the right ventricle (RV) with or 
without left ventricular (LV) involvement. The pathological hallmark of the disease is defined 
by progressive myocardial tissue loss with fibro-fatty replacement in an epicardial to an 
endocardial pattern.1,2 Affecting 0.02-0.10% of the European population, ARVC is considered 
autosomal dominant with incomplete penetrance in 30% of cases, with rare autosomal 
recessive variants described.3,4 The suspicion of ARVC is often made in otherwise healthy 
individuals presenting predominantly with lethal tachyarrhythmias, with or without overt 
structural cardiac abnormalities.1,3 Diagnosing ARVC can be difficult especially with a normal 
physical examination reported in at least 50% of patients. There is currently no single 
diagnostic modality available to confirm ARVC despite advancements in imaging technology, 
molecular genetics, and rhythm analysis.5  
 
In 1994, a Task Force from both sides of the Atlantic Ocean was established to aid in the 
diagnosis of ARVC. A set of task force criteria was proposed to facilitate the recognition of 
ARVC and to provide guidance on the interpretation of many frequently used diagnostic 
modalities.  Although highly specific, the 1994 criteria were based mainly on symptomatic 
cases in the advanced spectrum of disease, and therefore lacked sensitivity for the recognition 
of early and familial ARVC.6 In 2010, the revised Task Force criteria (TFC) was proposed to 
facilitate a clinical diagnosis in those with subtle disease expression. Designed to enhance the 
sensitivity of disease detection in probands previously classified as borderline using the 1994 
TFC, the 2010 TFC placed more weight on quantitative criteria, advanced imaging (using 
cardiovascular magnetic resonance – CMR), and repolarisation abnormalities (such as T-
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wave inversion) as early and sensitive markers of disease expression.6 Genotype analysis 
was also introduced and referenced as a major criterion in the 2010 TFC.   
The ARVC registry of South Africa (SA) was established in 2003. Africa’s first confirmed cases 
of ARVC were reported in 2004.7,8 Our ARVC registry served as a recruitment model for sub-
Saharan Africa (SSA) and was later absorbed into the African Cardiomyopathy and 
Myocarditis Registry Program (IMHOTEP) in 2015 (Kraus S. 2019. PhD Thesis. UCT). 
 
1.2      Data sourced  
Using an evidence-based approach, an extensive review of medical literature published in 
English involving human participants was carefully selected and indexed through PubMed as 
a primary database. Additional international and local databases relevant to the review were 
included using a similar search protocol. Key search words using a MeSH search strategy 
included: ‘arrhythmogenic right ventricular cardiomyopathy’, and ‘ARVC’. Filtered advanced 
searches included headings such as: ‘history’, ‘genetics’, ‘diagnostic criteria’, ‘1994 Task 
Force criteria’, ‘2010 Task Force criteria’, and ‘diagnostic modalities’. Non-human 
experimentations and ‘paediatrics’ were part of the exclusion search criteria. Articles up to 
May 2019 were included.  
 
1.3      Historical considerations and nomenclature  
In 1736, Giovanni Maria Lancisi, the Pope’s physician, identified a family with recurrent heart 
disease across four generations that presented with sudden cardiac death (SCD) and right 
ventricular failure. Published in a book entitled ‘De Motu Cordis et Aneurysmatibus’, this 
represented the first historic case description resembling ARVC.9 It was only two hundred and 
fifty years later in 1982 that the first comprehensive case report of ARVC as a clinical entity 
was published by Dr Frank Marcus. He described a case series of 24 patients with recurrent 
ventricular tachycardia and right ventricular (RV) enlargement with myocardium replaced by 
fibro-fatty tissue, and termed the clinical condition ‘right ventricular dysplasia’, later coined as 
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‘arrhythmogenic right ventricular cardiomyopathy/dysplasia’.10,11 The term dysplasia was 
abandoned when ARVC was incorporated into the World Health Organisation (WHO) 
nomenclature and classification of cardiomyopathies.12 Approximately 20-years later, ARVC 
was reported in Africa.7 
 
1.4      Epidemiology  
The global prevalence of ARVC is estimated between 1 in 2000-5000, with a male 
predominance of about 70% represented by a 3:1 ratio to females. The higher frequency in 
males may be linked to specific gender influenced high-intensity sport participation, or a direct 
influence of sex hormones on phenotypic disease expression.1 ARVC usually presents in the 
second to fourth decade of life, with a mean age of presentation at 40 years.11 Currently, ARVC 
is responsible for approximately 5-20% of SCD in the young athletic population globally.3 The 
annual international mortality rate of ARVC varies between 0.1-3%. A similar finding was 
represented in our ARVC registry of SA.13 
 
1.5      Pathogenesis  
The RV myocardial microanatomy can be described by two perpendicularly orientated layers 
of myocardial fibres. Distortion of these fibres occurs when cell-cell mechanical connections 
fail, creating an area of weakness prone to shearing forces during cardiac contraction.14 
Replacement of RV myocardium with fibro-fatty scar tissue, unique to ARVC, further leads to 
free wall thinning and aneurysmal dilatation. Severe or late disease typically manifests in areas 
of the RV collectively known as the ‘triangle of dysplasia’, represented by an inflow tract 
marked by the sub-tricuspid region (RV pulmonary outflow tract) and the RV apex.1 A 
pathognomonic site for ARVC related aneurysms commonly occurs in the inferior 
diaphragmatic wall below the posteroinferior leaflet of the tricuspid valve.2 The ‘triangle of 
dysplasia’, historically described in ARVC since 1982, is predominantly associated with severe 
cases, and not sensitive enough to apply to early disease manifestations. Over the past 
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decade, the perception of structural involvement of ARVC has changed to a new biventricular 
triangle involving the RV basal anteroinferior wall, and LV posterolateral wall (Figure 1). These 
findings represent early ARVC disease.15,16  
 
Figure 1. Triangle of dysplasia. 
A. Original triangle of dysplasia B. Revised bi-ventricular triangle of dysplasia. 
 
From: Mast, T., Teske, A., Doevendans, P., et al. Current and future role of echocardiography in 




ARVC is a desmosomal cellular junctional disease. Cellular connections are primarily 
established by gap junctions, adherens junctions, and desmosomes. Ultrastructural 
investigation of endomyocardial biopsies reveals intercalated disk remodeling with fewer and 
shorter desmosomes resulting in intercellular gap widening (Figure 2). Desmosomes are 
complex multiprotein structures principally responsible for mechanical and electrical 
attachment of adjacent cells. Mechanical uncoupling in ARVC is strongly associated with 
cellular death and fibrosis, while electrical uncoupling is associated with significant activation 
delay; both of these changes clinically manifest as lethal arrhythmias.15 Desmosomes are 
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formed from proteins originating from three separate subgroups: desmosomal cadherins, 
armadillo proteins (plakoglobin and plakophilin), and desmoplakins.  
 
Figure 2. Histopathological features of Arrhythmogenic Right Ventricular Cardiomyopathy.  
A. Normal desmosome. B. Abnormal desmosome   
 
From: Corrado D, Link MS CH, Calkins H. Arrhythmogenic Right Ventricular Cardiomyopathy. New Engl 
J Med. 2017;376:61–72. 
 
 
In the year 2000, a deletion in the plakoglobin gene was found in Naxos disease, an autosomal 
recessive variant of ARVC.13 The plakophilin-2 gene was later found to be the most frequently 
associated pathogenic genetic mutation in ARVC.13 Adipogenesis is believed to originate from 
mutated desmosomal plakoglobin proteins that induce intranuclear signaling, suppressing a 
canonical Wnt–β-catenin signaling pathway.17 Studies containing mutated plakoglobin have 
demonstrated increased expression of adipogenic and fibrogenic genes, contributing to the 
development of fibro-fatty myocardial replacement and scarring.1,9 Fibro-fatty tissue 
replacement in ARVC provides an additional substrate for arrhythmogenesis through scar-
related macro-reentry phenomena.1 Remodeling of intercalated discs and the subsequent 
widening of myocyte gap junctions, significantly contribute to the arrhythmogenicity of ARVC 
and the potentiate the risk of SCD.13 Adding to the complexity of diagnosing ARVC 
A B 
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intramyocardial fat deposition in the anterolateral and apical regions of the RV can be seen in 
normal hearts and is commonly associated with increased body habitus.13 
 
1.6      Genetic underpinnings  
ARVC is known as a ‘disease of the desmosome’.18 The first gene, desmoplakin (DSP) 
encoding the protein desmoplakin, was reported in 2002.19 Currently, five causative genes 
responsible for the coding of desmosomal proteins have been identified: namely junction 
plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2), and 
desmocollin-2 (DSC2). Other non-desmosomal genes such as transmembrane protein 43 
(TMEM43), cardiac ryanodine receptor (RYR2), and transforming growth factor-beta 3 
(TGFB3) have also been implicated in ARVC disease.20,21,22 The PKP2 gene is most commonly 
described and found in 25% of all cases with ARVC.23 In 2009, under the leadership of 
Professor Bongani Mayosi, new markers across the PKP2 locus were found in four unrelated 
Caucasian families in South Africa. These findings established a genetic founder effect 
originating from early Dutch settlers.11 Abnormal desmosomal genes have only been identified 
in 30-50% of patients with ARVC, highlighting the possibility of many undiscovered genes.24 
By using next-generation genetic sequencing, several non-desmosomal genes frequently 
found in other forms of cardiomyopathy, such as familial dilated cardiomyopathy, have been 
found to be associated with ARVC.15,18 The distinction between these inherited 
cardiomyopathies, with similar genetic and phenotypical characteristics, have crucial 
implications in clinical practice, a problem commonly encountered when diagnosing ARVC.18 
In 2017, our group described a pathogenic genetic variant of the CDH2 gene, that is 
responsible for the encoding of intercalated disc protein cadherin-2, as a novel genetic cause 
of ARVC.22 This unique finding in a three-generation family established new insights into the 
pathogenesis of ARVC not previously documented in medical literature.22 Fundamental 
genetic principles are imperative when interpreting genetic testing as only 16% of healthy 
individuals carry a mutation variant of ARVC.19 While positive genotyping is supportive, it is 
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not confirmatory of ARVC and should not override clinical judgement.25 A person who has a 
gene mutation inherits the risk of having the disease, but may not develop the disease.24 A 
significant family history changes the probability of developing ARVC from 1:1000-5000 of the 
general population, to a risk of 1:2.26 A negative genetic test is non-contributory to the 
diagnosis of ARVC as only 30-50% of probands carry a known defective gene.25  
 
Desmosomes are present in other parts of the human body besides the cardiac muscle.24 It 
has been found in skin and hair follicles in cardio-cutaneous autosomal recessive spectrums 
of ARVC. Naxos disease, one of the two cardio-cutaneous manifestations of ARVC,  presents 
with palmoplantar keratosis (thickening of palms and soles), woolly hair and features of 
ARVC.27 The second cardio-cutaneous variant was discovered in Ecuador and is known as 
the Carvajal syndrome which has a preference for the left ventricle.24 
 
1.7      The effect of exercise on ARVC 
Significantly higher pulmonary pressures and RV afterload is attained by athletes during 
exercise when compared to the LV.28 ARVC patients participating in competitive sport, such 
as soccer and basketball, have been shown to have a five-fold increased risk of SCD when 
compared to non-athletes.29. It has been postulated that fatal ventricular arrhythmias are 
attributed to exercise-induced RV wall stretching following the law of Laplace. Physical 
exercise further aggravates mechanical cellular uncoupling. Aerobic-exercise has been shown 
to increase pressure afterload and wall stress disproportionately in the RV compared to the 
LV (170% versus 23%), triggering malignant ventricular arrhythmias and promoting disease 
progression.1,30 Higher wall tension has been found to be an ideal site for mechano-
transduction, which is the conversion of mechanical stimuli to intracellular biochemical signals. 
Mechano-transduction enables cells to adapt to external forces and physical constraints, 
promoting the RV free wall to act as a potential pathological site in the setting of genetically 
frail intercellular junctions.9,31 Competitive sport has been associated with earlier symptom 
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presentations, larger RV volumes and carries a higher risk of SCD compared to recreational 
sport.3 Seventy-one percent of participants in competitive sports at risk for ARVC have 
inducible VT at electrophysiological studies, compared to 44% of participants involved in 
recreational sports.3 At 10-year follow-up, 40% of ARVC patients associated with competitive 
sport, presented with earlier symptoms compared to 7% in recreational sport.3 It is currently 
recommended that ARVC patients avoid competitive and most recreational sports, reducing 
their risk for ventricular arrhythmias and subsequent death.3,32 Examples of competitive 
sport include basketball, soccer, hockey, skiing, running, biking, and tennis; while examples 
of recreational sport include bowling, golf, weight-lifting and baseball.33,34 
 
1.8      Diagnosis  
Early disease ARVC is an exceedingly challenging diagnosis to make, especially when there 
are minimal structural or functional alterations of the RV present. Histological illustrations of 
transmural fibro-fatty replacement of RV myocardium is a valuable diagnostic indicator, 
however, not always possible. The segmental nature of ARVC makes endomyocardial 
biopsies (EMB) of the RV innately difficult, especially with the presence of RV adipose tissue 
in healthy individuals without ARVC.35 Misinterpretation of physiologic cardiac fat distribution 
in the RV apical wall often leads to an overdiagnosis of ARVC.16 Other conditions commonly 
misclassified as ARVC include idiopathic right ventricular outflow tract tachycardia (RVOT), 
cardiac sarcoidosis, congenital heart disease, and dilated cardiomyopathy, often mimic the 
biventricular variant or end-stage manifestation of ARVC.1 A diagnosis of ARVC relies heavily 
on the combination of structural, functional, histological and electrophysiological 
abnormalities. Scientific communities globally have recognised the difficulties in diagnosing 
ARVC and thus an international diagnostic task force was assembled. 35 
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1.9      1994 Task Force criteria 
In 1994, the Working Group of Myocardial and Pericardial Diseases of the European Society 
of Cardiology (ESC) and the Scientific Council on Cardiomyopathies of the International 
Society and Federation of Cardiology (ISFC) established a task force that proposed clinical 
criteria that would aid in the diagnosis of ARVC. Their aim was to facilitate the recognition and 
interpretation of non-specific clinical features of ARVC in conjunction with objective data from 
a combination of diagnostic modalities.35 The 1994 criteria were structured according to 
structural imaging, tissue characterisation, and rhythm abnormalities. Each section was 
categorised into major and minor criteria based on specificity and association with ARVC. A 
definite diagnosis of ARVC was established by fulfilling either two major criteria; or one major 
plus two minor criteria; or with four minor criteria.35  
 
The 1994 TFC concentrated on symptomatic indexes and SCD, representing an advanced 
spectrum of disease. The criteria focused predominantly on RV disease, reserving the 
involvement of the LV as a marker of exclusion as of its common association with other 
cardiomyopathies. The 1994 TFC was deemed highly specific but lacked sensitivity for the 
recognition of early and familial diseases which often have incomplete expression.6 Structural 
and functional imaging criteria were based on a qualitative rather than a quantitative approach 
that was incorporated in the 2010 TFC. The criteria were also referenced according to 
literature that lacked our current knowledge and experience with advanced imaging such as 
cardiovascular magnetic resonance (CMR).36 Major 1994 TF imaging criteria using either 
echocardiography, CMR or right ventricular angiography (RVA), required severe dilatation and 
reduction in RV systolic function without LV impairment, localised RV aneurysms with akinesia 
or dyskinetic areas, or severe segmental dilatation of the RV. Minor imaging criteria was 
represented by either mild global RV dilatation with reduced ejection fraction and normal LV, 
mild segmental dilatation of the RV free wall, or isolated regional RV hypokinesia.13 The 1994 
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TF imaging criteria, although helpful, lacked specific quantitative cut-off parameters for grading 
RV dysfunction according to gender determining body surface area.36  
 
In the early 1990s, endomyocardial biopsy (EMB) was heavily weighted and considered the 
preferred method for diagnosing ARVC. The 1994 TFC incorporated findings from EMB as 
major criteria, however, these criteria lacked morphometric analysis of myocytes that were 
replaced by fibro-fatty tissue, an important differentiator from physiological adipogenesis and 
other cardiac conditions (Figure 3). EMB has a low sensitivity of 67% and higher specificity of 
91.5% for diagnosing ARVC.37 As experience using EMB developed, it became more clearer 
that EMB held very low diagnostic influence in diagnosing ARVC than it was previously 
thought. Tissue sampling, predominantly taken at the junction of the ventricular septum and 
free wall, carries a low risk (0.2%) of perforation, however, due to the segmental nature of 



















Figure 3. Endomyocardial biopsy sample of an ARVC patient.   
Histology specimen of the RV myocardium showing evidence of fibro-fatty infiltration (elastic von 
Gieson stain, magnification ×100). 
 
From: Mayosi BM, Fish M, Shaboodien G, et al. Identification of Cadherin 2 (CDH2) Mutations in 
Arrhythmogenic Right Ventricular Cardiomyopathy. Circ Cardiovasc Genet. 2017;10(2). 
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Cardinal diagnostic information obtained by current advancements in medicine were often 
excluded or designated a minor contributory status in the 1994 TFC. Many diagnostic findings, 
now prioritised as major criteria in the 2010 TFC, such as right precordial T-wave inversion 
(TWI) and arrhythmias of RV origin, were weighed less as of their association with other 
cardiac conditions. With the 1994 TFC directed predominantly at the severe spectrum of 
ARVC, a new approach facilitating an early clinical diagnosis was needed. The new TFC 
needed to incorporate advancements in technology and improve diagnostic sensitivity while 
maintaining the diagnostic specificity of the 1994 TFC.6 
 
1.10   2010 Revised Task Force criteria 
Fifteen years after their first meeting, the ARVC task force was re-convened to revise the 
original ARVC diagnostic criteria. Advancements in medical science, imaging and genetics 
helped design the current 2010 TFC, placing new emphasis on identifying patients in the early 
phase of ARVC. Although the 2010 TFC was structured to maintain established diagnostic 
specificity, the sensitivity of probands previously diagnosed as borderline using the 1994 TFC 
was increased.26,36 An essential prerequisite in the establishment of the 2010 TFC was the 
maintenance of categories structured in the original 1994 TFC.18 The new criteria maintained 
the original sub-divisions of six categories, namely structural abnormalities, tissue 
characterisation, repolarisation abnormalities, depolarisation abnormalities, arrhythmias, and 
family history. According to the 2010 criteria, a definite diagnosis of ARVC was made by 
fulfilling either 2 major; 1 major and 2 minor; or 4 minor criteria. A borderline diagnosis of 
ARVC required 1 major and 1 minor; or 3 minor criteria. A possible diagnosis of ARVC would 
require 1 major; or 2 minor criteria.25 The previous TFC was greatly limited by subjective 
assessments used to meet imaging criteria, particularly when assessing ventricular structure 
and function. As a consequence, the revised 2010 criteria focused strictly on quantitative 
measurements.40 Separate imaging major and minor criteria defining morphologic RV changes 
for echocardiography and CMR were included, and no longer limited to previously stipulated 
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RV regional hypokinesis, microaneurysm and segmental dilatation. To fulfil new imaging 
criteria, regional wall motion abnormality had to be accompanied by global RV dilatation based 
on precise gender-specific volumetric measurements and indexed to body surface area or RV 
systolic dysfunction.36  
 
A great shortfall of the 1994 criteria was the frequent misinterpretation of normal RV function 
as local ‘hypokinesis’, resulting in large amounts of interobserver variability and overdiagnosis 
of ARVC. The terminology ‘hypokinesis’ was subsequently abandoned from the new criteria.41 
Further improvements of the 2010 criteria included the incorporation of both RV functional as 
well as structural wall motion abnormalities, rather than simple ‘hypokinesis’ term previously 
used in establishing a diagnosis.41,42  The 2010 imaging TFC used terminology such as 
‘akinesia’ which was defined as a lack of motion, ‘dyskinesia’ defined as an abnormal outward 
myocardial bulge during systole, and ‘dyssynchronous’ expressed as regional contractions of 
surrounding myocardium at different times. These terminologies were standardised and used 
across all three imaging modalities (echocardiography, CMR and RVA) when assessing 
regional wall motion abnormalities in ARVC.15 Fifteen years of medical progression was 
successfully incorporated into the 2010 TFC with the aim of improving the diagnostic sensitivity 
of detecting early ARVC while establishing a diagnosis in those previously diagnosed as 
borderline ARVC according to the 1994 TFC.26  
 
1.11  Diagnostic imaging modalities   
 
1.11.1      Echocardiography 
Revised 2010 TF imaging criteria for two-dimensional echocardiography focused particularly 
on quantitative RV outflow tract measurements and areas of fractional change for RV systolic 
function. The 2010 TFC also included qualitative features by commenting on the presence of 
regional RV akinesia, dyskinesia, or aneurysms.43 Echocardiography is often limited by 
technique as the desired quantitative information of RV function is challenging to acquire. A 
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considerable amount of difficulty arises when attempting to visualise the complex RV anatomy 
that is shielded by the sternum, requiring special views that are not always easy to acquire in 
a standardised transthoracic echocardiographic study. Hence to diagnose ARVC by 
echocardiography is challenging, and requires a high level of expertise.44 A further limitation 
when using two-dimensional echocardiography is its weak correlation with CMR-based 
measurements of RV dilatation and function. Although quantitative measurements have 
significantly increased TFC sensitivity and specificity when evaluating the RV, technique and 
probe angulation often reveal variable results even in experienced hands. The segmental 
nature of ARVC and poor acoustic windows generated by the RVOT makes visualisation of 
RV dilatation difficult and a reason for reduced fulfilment of echocardiography-based TFC.45 
Discrepancy in fulfilling imaging diagnostic criteria have clinical implications since imaging 
data is a pivotal diagnostic criterion in a significant number of cases.45  
 
1.11.2 Cardiovascular magnetic resonance (CMR) 
CMR, with specific quantitative and qualitative measurements, has been a significant addition 
to the revised TFC. CMR qualitative measurements describe RV wall motion abnormalities as 
either regional akinesia, dyskinesia, or with dyssynchronous contraction, while its quantitative 
measurements assess RV end-diastolic volume by body surface area and ejection fraction. 
The strict quantitative values depicted in the 2010 TFC were standardised using healthy 
volunteers from the Multi-Ethnic Study of Atherosclerosis (MESA) as controls when compared 
to ARVC probands in the North American ARVC registry.15 CMR, by its high spatial resolution 
and unlimited orthogonal imaging planes, is currently revered for its precise RV volume and 
systolic function assessment (Figure 4). Together with high intra-observer and inter-observer 
agreement and accuracy, CMR has become the preferred non-invasive diagnostic tool for the 
evaluation of the complex RV anatomy.15,36  
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Figure 4: Sample CMR short axis of a normal (A) versus an ARVC patient (B).  
A. Normal RV (yellow arrow) B. Isolated dilatation and thinning of the RV with segmental RV free 
wall aneurysm (yellow arrows). 
 




CMR can also characterise tissue and enhance identification of intra-myocardial fat and 
fibrosis by using late gadolinium enhancement (LGE). CMR, when available, offers a wealth 
of reliable data and is slowly becoming the chosen imaging modality in ARVC.44 Although LGE 
can be used to assess myocardial fibro-fatty infiltration and distinguish ARVC from other 
cardiomyopathies, there is still some uncertainty on its diagnostic targets and it may carry a 
risk for the overdiagnosis of ARVC. Additional limiting factors on LGE include the 
enhancement of RV fat in healthy individuals and the persistent difficulty in differentiating fat 
from fibrosis in relatively thin RV myocardium. Using LGE highlights a risk of overdiagnosing 
ARVC, and is not currently part of the current imaging criteria for ARVC.36  
CMR is seen as an excellent modality when screening asymptomatic relatives at risk of ARVC 
especially because the sensitivity of echocardiography in these patient populations remain 
unacceptably low.45 The major disadvantage of CMR rests in its limited availability and the 
need for high-level expertise during the assessment and interpretation of data.44 Unfortunately 
A B 
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despite CMR being an attractive field for training at many academic institutes, clinical 
experience remains challenging to acquire as of low disease prevalences.15 Despite CMR 
emerging as the favoured imaging modality when diagnosing ARVC, electrical abnormalities 
often precede structural changes in ARVC, emphasising a reason why CMR should not be 
used in isolation when diagnosing ARVC.15 
 
1.11.3     Right ventricular angiography (RVA) 
RVA allows for global and regional analysis of the RV anatomy. Fulfilment of quality imaging 
criteria by the presence of dyskinetic or akinetic myocardium in the infundibular, apical or sub-
tricuspid regions of the RV, has a 90% specificity for ARVC.46 On the contrary, even with good 
quality angiograms, it is often difficult to assess the complex geometric shape of the RV and 
thus a negative angiogram does not exclude ARVC.47 Despite offering detailed functional 
anatomy, RVA’s are limited by its invasive, time-consuming nature that lacks qualitative 
imaging standardisation that generates a high amount of inter-observer variability.48 Clinicians 
have thus moved away from RVA as a preferred diagnostic modality. 
 
 
1.12  Rhythm Analysis  
 
1.12.1     Electrocardiography (ECG) 
The 2010 TFC subdivide ECG findings according to repolarisation and depolarisation 
abnormalities. The inclusion of repolarisation abnormalities, an early marker for ARVC, in the 
revised TFC represents an evolution in the TFC.   
 
Repolarisation abnormalities  
Repolarisation abnormalities, a primary diagnostic feature in ARVC, are early and sensitive 
markers of disease expression.6 These abnormalities, found in individuals older than 14 years 
in the absence of a right bundle branch block (RBBB), are defined as major criteria in the 2010 
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TFC when T-wave inversion (TWI) in right precordial leads extend from lead V1 to V3.49 
Anteroseptal TWI (V1-V3) are uncommon in patients with a RBBB who do not have ARVC.40 
Characteristically, this particular pattern of TWI is seen in 87% of patients with ARVC and only 
present in <3% of healthy individuals without ARVC.50 Interestingly, anteroseptal TWI is 
commonly found in 12.7% of black athletes and can be differentiated from ARVC by the 
presence of preceding convex ST-segment elevation, a finding rarely found in ARVC.41,51  
Pre-participation athletic screening programs introduced in Italy in 1982 have substantially 
decreased SCD in young competitive athletes.52 Cardinal ECG observations including right 
precordial TWI, QRS widening and epsilon waves have led to athletic disqualification and has 
resulted in a sharp decline in ARVC-related SCD during sporting activities globally.9  
 
Depolarisation abnormalities  
Depolarisation abnormalities represent markers of intraventricular conduction delay. 
Electrophysiologically, these abnormalities, a common feature found in the severe spectrum 
of ARVC, denote surviving myocardium interspersed between fibro-fatty tissue that fragments 
electrical current.13 Ventricular depolarisation abnormalities in ARVC are confined to 
conduction delay in right precordial leads (without a RBBB) and are represented by coined 
abnormalities referred to as epsilon waves, late potentials (typically described using signal-
averaged ECG), and terminal activation delay of the QRS complex. An epsilon wave (Figure 
5), first described in 1977 by Dr Guy Fontaine, is a post-excitation ventricular wave occurring 
in 30% of cases with ARVC.47,53 Commonly small in amplitude; the epsilon wave mirrors a pre-
excitation delta wave by occurring after the QRS complex at the start of the ST-segment. 
Epsilon waves are a histopathological representation of delayed activation in RV myocardial 
fibres and are considered an electrophysiological substrate for ventricular 
tachyarrhythmias.14,47  
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Figure 5: Sample ECG of an ARVC patient.  
B. Depolarisation changes in the form of an Epilson wave in V1. B. Repolarisation changes with 
TWI from V1-V5. 
 
From: Nasir, K., Bomma, C., Tandri, H., et al. Electrocardiographic features of arrhythmogenic right 





1.12.2      Signal-averaged electrocardiography (SAECG) 
SAECG is a diagnostic modality used to assess for late potentials and populates minor 
depolarisation TFC. It averages multiple consecutive QRS complexes (approximately 250) 
and filters random noise. Late potentials are defined as prolongation of right precordial QRS 
complexes and assessed by having either: 
1) a filtered QRS duration (using a 40-250Hz filter) ≥ 114ms,  
2) duration of low terminal signal QRS (<40 mV) ≥ 38ms, and/or  
3) root-mean-square voltage of a QRS terminal 40ms ≤ 20 mV.  
 
If ≥ 1 of these abnormal parameters are found, a minor depolarisation criterion for ARVC is 
fulfilled. Analysis of each parameter has a sensitivity ranging from 58 to 60% with a specificity 
A 
B 
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of 94 to 96%.40 Abnormal SAECG is not specific for ARVC, and is seen in other conditions 
with abnormal myocardial tissue.44 Despite its weak contribution to TFC, it remains a useful 
non-invasive tool for screening ARVC in family members.47 
 
1.12.3      Terminal activation duration (TAD) 
TAD is demonstrated in QRS complexes found in anteroseptal precordial leads (V1-V3) with 
delayed S-waves exceeding 55ms. It is a manifestation of conduction delay and contributes 
one minor depolarisation criterion to the 2010 TFC. TAD is measured from the nadir of the S-
wave to the end of depolarisation. Although epsilon waves are defined as separate entities 
found at the end of QRS complexes; ambiguity often arises when its end is not clearly 
demarcated. TAD avoids this dilemma by including the last depolarisation deflection in its 
measurement (i.e. including epsilon waves if present).44 Duplication of TFC is always a 
concern when working with overlapping modalities, however, duplicated TFC is fundamentally 
prevented as one can only fulfil either major or minor criteria, and never both. The limitation of 
TAD is seen in its contra-indication in complexes with a RBBB, an uncommon finding in 
patients with ARVC and TWI in V1-V3.6 
 
1.12.4     Arrhythmias  
Sustained or non-sustained (<30 seconds) ventricular arrhythmias originating from the RV 
inferior wall or apex are considered major criteria for ARVC. The VT’s QRS morphology and 
axis help reflect its site of origin. A superior axis is defined as a predominantly negative or 
indeterminate QRS complex in leads II, III, and aVF and a positive QRS complex in lead aVL. 
An inferior axis is defined as a predominantly positive QRS complex in leads II, III, and aVF 
and a negative QRS complex in lead aVL. A VT with a left bundle branch block (LBBB) 
morphology and inferior axis suggests an origin from the RV outflow tract (RVOT), fulfilling a 
minor criterion according to the 2010 TFC. Importantly, a VT with a LBBB morphology and 
superior axis suggests origins in the RV inferior wall and fulfils a major criterion.44 
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Characteristically, patients with ARVC and a near-normal LV function, tolerate a sustained RV 
VT ranging between 200–250 beats/minute for many hours before presentation.41 
 
1.12.5     24-hour Holter monitoring 
Although the presence of ventricular ectopy increases with age, >200 premature ventricular 
complexes (PVC’s) in 24-hours in an adult <50 years is suggestive of an underlying myocardial 
disease, not explicitly ARVC.40 A Holter measuring >500 PVCs in 24-hours satisfies a minor 
(arrhythmia) criterion in the 2010 TFC. Due to the limited number of leads used in the Holter, 
no restricted QRS PVC morphology is stipulated in the 2010 TFC.44 Although represented as 
a tool for investigating ARVC, 24-hour Holter devices are particularly useful in monitoring 
patients with ARVC.  
 
1.13  Family History  
The 2010 TFC incorporated the evolving genetic background of ARVC by including genotyping 
as a diagnostic modality that contributes a major criterion towards diagnosing ARVC. 
 
1.13.1  Genotyping 
The variability of the genotypic–phenotypic presentations of ARVC, especially with incomplete 
penetrance, creates an unclear risk of inheritance in family members.51 Asymptomatic 
relatives with desmosomal mutations have a six-fold increased risk of developing ARVC 
compared to family members of probands without a pathogenic mutation.54 Although 
genotyping is integrated as a tool for screening early disease, in light of its flaws at predicting 
disease, genetic counselling is emphasised.15  
 
1.14  The rationale for this study 
ARVC manifests with life-threatening arrhythmias in the young, economically active 
population. Structural abnormalities in ARVC are easily overlooked, especially in the early 
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stages of disease when the diagnosis is challenging. With non-specific clinical findings and no 
gold standard investigation to diagnose ARVC, the best strategy rests in the combination of 
highly sensitive and specific criteria from selected evidence-based diagnostic modalities to 
improve diagnosis.55 Importantly, ARVC needs to be distinguished from other inherited 
cardiomyopathies with similar genetic and phenotypical characteristics.18  
 
The ARVC registry of South Africa was established in 2003 (HREC: 047/2003) under the 
auspices of the Cardiac Arrhythmia Society of South Africa (CASSA) at GSH.8,23 The objective 
of this registry was to determine the clinical characteristics, survival, and genetics of ARVC in 
South Africa. Published previously, fifty unrelated cases who met the 1994 TFC were enrolled 
between January 2004 and April 2009. The mean age of symptom onset was 32.6 years with 
a male predominance of 66%.23 Professional endurance athletes represented 28% of the 
cohort.56 The mean age at death was 36.9 years, an early mortality no different to the general 
population of South Africa whose lifespan was shortened mostly to the epidemics of HIV/AIDS 
at that time.56 The cohort revealed an annual mortality rate of 2.8% in 2010, with a five-year 
cumulative mortality of 10%. Emphasis must be placed on the fact that participants were in 
the advanced phase of ARVC.56 The ARVC registry of South Africa was later absorbed into 
the African Cardiomyopathy and Myocarditis Registry Programme (IMHOTEP) in 2015 
(HREC:767/2014), and approved by the Human Research Ethics Committee of UCT. The 
IMHOTEP registry is designed to improve the diagnostic classification of cardiomyopathy, 
determine the role of genetics and myocarditis in the pathogenesis of the disease, and 
establish long-term outcomes. For the first time, participants suspected to have ARVC in 
IMHOTEP have been classified using both Task Force criteria. Re-analysis would help identify 
a diagnostic change in cases previously categorised using the 1994 TFC. This study will help 
discuss the clinical impact TFC have on predicting genotype status in a resource-restricted 
environment.  
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Chapter 2 - Methods  
 
2.1  Aims and Objectives 
Our study aimed at comparing the utility of the original 1994 TFC to the revised 2010 TFC 
(Table 2.1) in diagnosing mutation-positive unrelated probands with ARVC in the IMHOTEP 
study. Probands were defined as the first affected individual in a family seeking medical 
attention for ARVC (i.e. index case in a family). The following objectives were considered: 
 
Primary objectives 
1. All index cases (probands) referred with the suspicion of ARVC to the ARVC registry 
of South Africa and/or IMHOTEP registry were reassessed according to the 1994 
TFC.  
2. All index cases (probands) referred with the suspicion of ARVC to the ARVC registry 
of South Africa and/or IMHOTEP registry were reassessed according to the revised 
2010 TFC.   
3. A comparison of the diagnostic yield using both TFC was made, identifying a 
diagnostic change in a sub-Saharan African setting. 
 
Secondary objective  
1. A comparison of the diagnostic yield of the TFC and of the diagnostic modalities used 
when diagnosing ARVC in the South African cohort, were made against groups 
described internationally. 
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Table 2.1 Comparison of original 1994 and revised 2010 TFC 
From: Marcus FI, et al. Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: 
Prosed Modification of the Task Force Criteria. Circulation 2010;121:1533-1541. 
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Table 2.1 continued  
 
From: Marcus FI, et al. Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: 
Prosed Modification of the Task Force Criteria. Circulation 2010;121:1533-1541. 
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2.2      Methodology 
 
2.2.1  Study population and study design 
We performed a retrospective analysis of all participants referred with the suspicion of ARVC 
to the established ARVC Registry of South Africa (HREC: 049/2003) and IMHOTEP registry 
(HREC: 766/2014) between May 2003 and May 2018. Groote Schuur hospital is a multicentre 
referral point for ARVC in sub-Saharan Africa. Over the study period, 162 participants were 
referred to the registry from both private and public healthcare institutions in South Africa, with 
a majority of referrals originating from the Cardiac Clinic at Groote Schuur hospital, Cape 
Town. Participants of all ages were eligible for inclusion; however, as the diagnostic criteria 
do not apply to young children, individuals <14 years at the time of diagnostic evaluation were 
excluded. Participants were also excluded from the analysis if they had insufficient clinical 
data available for review. Informed consent for partaking in research was taken from 
participants by the ARVC registry of South Africa and/or IMHOTEP investigators at the time 
of participant recruitment. 
 
2.2.2  Diagnostic evaluation 
Original clinical data were gathered for all referred participants and reviewed by the IMHOTEP 
diagnostic panel (DP), comprising of clinicians specialised in clinical cardiology, 
electrophysiology, imaging (including CMR), pathology, and clinical and molecular genetics at 
the Cardiac Clinic, Groote Schuur hospital. The DP’s primary role was to confirm a diagnosis 
of ARVC by reviewing the medical history and investigations performed for each participant. 
To generate consistent data for diagnostic comparison using both the 1994 and 2010 TFC 
across the cohort, outcomes from imaging modalities such as echocardiograms, CMR and 
RVA, together with EMBs, and electrophysiological rhythm analysis using ECGs, SAECGs 
and 24-hour Holter monitoring were analysed. All quantitative studies were performed in a 
single academic institute by the DP. Due to cost and resource limitations, tissue re-
characterisation using histomorphometric tissue analyses, as defined in 2010 TFC, was only 
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performed on participants where a positive result would affect diagnosis and subsequent 
management. The DP classified participants according to the original 1994 TFC and revised 
2010 TFC, placing each participant into either a definite (2 major, or 1 major plus 2 minor, or 
4 minor criteria), borderline (1 major plus 1 minor, or 3 minor criteria), possible (1 major, or 2 
minor criteria) or no criteria (0 major, or 0 minor criteria) category. A confirmed diagnosis of 
ARVC for inclusion into IMHOTEP by the DP was based on the following criteria: 
1. A classification of either definite or borderline ARVC according to the revised 
2010 TFC (current standard of care); and 
2. The exclusion of alternative pathologies/diagnoses that may mimic ARVC.  
 
For this study, participants were divided into 2 arms, ‘DP included’ (i.e. confirmed clinical 
diagnosis of ARVC) and ‘DP excluded’ (i.e. insufficient criteria to diagnose ARVC - possible 
early ARVC, or alternative diagnosis). Further subdivision of the ‘DP included’ cohort was 
made according to genotype status. These were referred to as mutation-positive, mutation-
negative and mutation-unknown in the study. Genotype status was provided by the IMHOTEP 
investigators were mutation analysis was done for desmosomal genes encoding plakophilin-
2 (PKP2), desmoplakin (DSP), desmoglein-2 (DSG2), desmocollin-2 (DSC2), plakoglobin 
(JUP), and non-desmosomal genes encoding phospholamban (PLN) and cadherin 2 (CDH2) 
for index patients, and reported at the cardiovascular molecular genetics laboratory, Hatter 
Institute, UCT (Kraus,S. 2019. Ph.D. Thesis, UCT; Mbele, M. 2014. Ph.D. Thesis, UCT; Fish, 
M. 2016. Ph.D. Thesis, UCT; Machipisa, T. 2016. M.Phil. Thesis, UCT; Kamuli, S. 2016. 
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Table 2.2 Mutation status 
Mutation status Definition 
Mutation-positive The presence of a known pathogenic genetic variant (mutation) defined by 
the following criteria:  
1. associated with ARVC,  
2. unobserved or rare in large control populations, and  
3. alters or is predicted to alter the structure or function of protein, or 
linkage to a disease phenotype that has been demonstrated in a 
conclusive pedigree.6 
 
Mutation-negative The absence of a known pathogenic variant in participants who have 
undergone molecular genetic analysis. 
 
Mutation-unknown Participants were the genotype status is unknown as molecular genetic 
analysis has not yet been performed. 
 
 
As in our primary objectives, all index cases referred for the diagnosis of ARVC were re-
assessed according to both the original 1994 and the revised 2010 TFC (Figure 6 and 7) to 
compare the yield of the two diagnostic criteria in a sub-Saharan African setting. Our rationale 
for these objectives is that participants referred to the ARVC Registry prior to 2010 would have 
been included or excluded based exclusively on the fulfilment of the 1994 TFC.  In order to 
accurately compare the performance of the 1994 versus the 2010 TFC, and minimise clinician 
interpretation bias, the original diagnostic classifications done by the ARVC registry 
investigators were not used in this study. 
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Figure 6. Schematic representation of primary objectives in the ARVC registry 




Figure 7. Schematic representation of primary objectives according to mutation status 
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2.2.3  Data collection 
Diagnostic classification of data according to the 1994 and 2010 TFC were captured using 
prepared case report forms (appendix 1 and 2, respectively) by the DP and subsequently 
transferred into an electronic database. In addition to diagnostic data, baseline demographics 
(age at presentation, gender and ethnicity) were collected for each participant at the time of 
recruitment into the registry or collected from hospital records. Symptoms at presentation, 
including those who presented after surviving a sudden cardiac arrest and ventricular 
tachycardia, were also included in the analysis. Data was recorded on an online database, 
OpenClinica®. Unique study numbers previously assigned by the ARVC registry and/or 
IMHOTEP were used, respecting participant confidentiality.  
 
2.2.4  Ethical considerations 
Our study was conducted under the ethics approval (HREC REF: 454/2016) given by the 
Human Research Ethics Committee (HREC) at our institution (appendix 4) and was registered 
as a sub-study under the African Cardiomyopathy and Myocarditis Registry Program: 
IMHOTEP (HREC 766/2014) (appendix 3). The ARVC registry of South Africa (HREC 
047/2003) was incorporated into IMHOTEP at the time of its inception and approved by HREC 
in October 2014.  Our research was grounded by ethics, holding participant safety, rights, and 
well-being as a priority in keeping with the South African principles of Good Clinical Practice 
(GCP). Informed consent for partaking in research (including genetics analysis) was provided 
by participants (or their legal guardian in the case of minors) at the time of recruitment into the 
ARVC Registry of South Africa and/or IMHOTEP. 
 
2.2.5  Safety 
Structured as a low-risk retrospective observational study, collected data offered no potential 
harm to each participant’s standard of care. All obtained information complied with the Data 
Protection Act, 1998. To maintain a chain of confidentiality, participant records were 
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requested, analysed and returned based on strict security precautions outlined in the study 
protocol. A unique identifier was assigned to each participant, avoiding capture of identifiable 
personal information. Results from the TFC classification of participants evaluated by the DP 
were made available to attending clinicians of participants referred, especially if data held 
future management implications.   
 
2.2.6  Statistical methods 
Statistical analysis was performed using International Business Machines (IBM) Statistical 
Package for Social Sciences (SPSS) 2017 (Version 25.0, Chicago, USA). Descriptive statistics 
were used to describe study population data. Categorical data were presented as a number 
of cases and percentage, and the Chi-squared test was used to determine statistical 
differences between groups. Continuous data were tested for distribution using histogram for 
visualisation and Shapiro-Wilks for test of normality. Continuous variables were presented as 
either mean ± standard deviation (normally distributed data), or median and ± interquartile 
range (non-normally distributed data). Statistically significant differences between groups 
were determined using T-test (2 samples) or ANOVA table (more than 2 samples) for normally 
distributed data, and Wilcoxon sum rank (2 samples) and Kruskal-Wallis (more than 2 
samples) for non-normally distributed data. Levene’s test was used to verify the equality of 
variances. The McNemar test was used to determine differences in classification using the 
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Chapter 3 - Results 
 
One hundred and sixty-two participants with suspected ARVC were referred to the ARVC 
registry of South Africa and/or IMHOTEP registry between May 2003 and May 2018. Of those 
referred, 12 participants were excluded at the outset; 5 were incorrectly classified on the 
consent form and were not suspected of having ARVC, and a further 7 had insufficient clinical 
information available to complete either TFC (clinical data unavailable, n=4; histological 
diagnosis made at postmortem or post-transplant, n=2; infant, n=1). One hundred and fifty 
participants were included in this study and evaluated by the DP (Figure 8).  
Figure 8. Schematic representation of the ARVC Registry and/or IMHOTEP 
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Of the cohort of 150 unrelated participants, 68 were diagnosed with ARVC by the DP and 
included into the ARVC registry (i.e. ‘DP included’). Of those diagnosed with ARVC, 14 
participants were mutation-positive (PKP2 gene, n=12, CDH2 gene, n=2), 43 were mutation-
negative, and 11 were mutation-unknown. The remaining 82 participants were found to have 
an alternative diagnose or possible early ARVC (i.e. insufficient criteria to confirm ARVC) and 
were therefore excluded from the ARVC registry by the DP (i.e. ‘DP excluded’). Twenty-four 
percent of those excluded were thought to have possible early ARVC with insufficient criteria 
at baseline and follow-up to confirm a diagnosis. Seventeen percent were found to have 
different types of cardiomyopathy (dilated cardiomyopathy, n=5; hypertrophic cardiomyopathy, 
n=5; endomyocardial fibrosis, n=1; left ventricular noncompaction, n=1; and myocarditis, n=2), 
14.6% had idiopathic right ventricular outflow tract ventricular tachycardia (RVOT VT), 6.1% 
had a supraventricular tachycardia, 3.7% had athletes heart, 2.4% had cardiac sarcoidosis, 
and 14.6% had a non-cardiac diagnosis (Figure 9).  
 
 













Arrhythmia - RVOT VT, n = 12 Arrhythmia - SVT, n = 5 Arrhythmia - other, n = 13
Athletes heart, n = 3 Cardiomyopathy - sarcoid, n = 2 Cardiomyopathy - other, n = 12
Possible early ARVC, n = 20 No cardiac diagnosis, n = 12 Other, n = 3
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3.1       Baseline characteristics of all cases referred to the ARVC Registry 
 
The mean age of participants referred was 35.9 ±14.9 years with a male predominance of 
64.7%. Participant ethnicity comprised predominantly of Caucasian (55.3%), followed by 
mixed ancestry (29.3%), black African (10.7%) and Indian (4.7%). Symptoms at presentation, 
in descending order of frequency, were palpitations (71.3%), presyncope (46%), syncope 
(34%), chest pain (32.7%) and dyspnoea (20.7%). Very few cases (3.3%) were asymptomatic 
at the time of referral. There were no significant differences in mean age, gender, ethnicity or 
symptoms at presentation between the ‘DP included’ and ‘DP excluded’ cohort, with the 
exception of presyncope (55.9% versus 37.8%, p=0.039). There was, however, a significant 
difference in sustained VT at presentation between these groups; with VT occurring in 54.4% 
of those in the ‘DP included’ cohort and only in 31.7% of those in the ‘DP excluded’ group 
(p=0.008). There was no difference in the frequency of survived SCD between the groups 





























 SD = standard deviation; IQR = interquartile range.  
#VT = sustained ventricular tachyarrhythmias lasting greater than 30 seconds.   
*p-value represents the comparison between demographic characteristics in the ‘DP included’ (n=68) and ‘DP 
excluded’ (n=82) cohort.  
 
Age of onset = testing for normality varied between categories; therefore, both mean (±SD), and median (±IQR) 
are represented. Multiple tests applied (including Skewness, Kurtosis, Shapiro-Wilk, and visualisation with 
histogram, Q-Q plot and box plots) with varying results. Shapiro-Wilk test for all cases, p= 0.011; ‘DP included’ 






Table 3.1.1. Baseline demographic characteristics of all cases referred to the ARVC 
                    Registry 
Participant characteristics Cases referred to 
ARVC registry, 
n=150 (%) 
Comparison between  
‘DP included’,  
n=68 (%) 
‘DP excluded’,  
n=82 (%) 
p-value* 
Age of onset in years 
     Mean (±SD) 
     Median (±IQR) 
 
35.9 (14.9) 
37 (23.8 - 46.0) 
 
35.6 (13.8) 
38 (25.3 - 44.8) 
 
36.2 (15.8) 




Male 97 (64.7) 45 (66.2) 52 (63.4) 0.725 
Ethnicity  
     Caucasian  
     Black African 
     Mixed ancestry (Coloured) 



















Symptoms at presentation 
     Palpitation 
     Presyncope 
     Syncope  
     Chest pain   
     Dyspnoea 
     Asymptomatic 
     Symptoms unknown 
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When comparing the baseline characteristics of those with ARVC (n=68) according to 
mutation status (mutation-positive versus mutation-negative), there were no significant 
differences found in gender, ethnicity or symptoms at presentation between the groups (Table 
3.1.2).  There was, however, a significant difference in the age of onset between mutation-
positive and mutation-negative participants (mean age in years, 28.5 ± 13.96 versus 39.4 ± 
12.91, p=0.009). Mutation-positive participants were also more likely to present with VT than 
those who were mutation-negative (78.6% versus 46.5%, p=0.036). 
 
 











Age of onset in years 
     Mean (±SD) 




28 (14.5 - 44) 
 
39.4 (12.91) 
39.0 (32 - 47) 
 
29.8 (12.64) 






9 (64.3) 28 (65.1) 8 (72.7) 0.955 
Ethnicity  
     Caucasian 
     Black African 
     Mixed ancestry (Coloured) 




















     Palpitation 
     Presyncope 
     Syncope  
     Chest pain 
     Dyspnoea 
     Asymptomatic 
     Symptoms unknown 
 














































SD = standard deviation; IQR = interquartile range.  
*p-value represents the comparison between demographic characteristics in the mutation-positive (n=14) and 
mutation-negative (n=43) cohort. 
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3.2       Diagnostic classification of all cases referred to the ARVC Registry  
      according to the 2010 and 1994 TFC  
 
When comparing the 2010 and 1994 TFC in the ‘DP included’ group (n=68); 52 (76.5%) versus 
47 (69.1%), [McNemar test, p=0.267] were found to have a definite diagnosis of ARVC, and 
16 (23.5%) versus 12 (17.6%) [McNemar test, p=0.503] fulfilled borderline criteria. Nine 
participants classified as definite or borderline ARVC using the 2010 TFC were classified as 
possible (n=8, 11.8%) or no criteria (n=1, 1.5%) when using the 1994 TFC, respectively (Table 
3.2.1 and 3.2.2; or Figure 10). Comparatively, when using the 2010 versus 1994 TFC in the 
‘DP excluded’ cohort, 4 (4.9%) versus 9 (11%) [McNemar test, p=0.180] participants fulfilled 
criteria for a definite diagnosis, and 3 (3.7%) versus 16 (19.5%) [McNemar test, p=0.002] were 
classified as borderline (Table 3.2.1). Importantly, 7 of the ‘DP excluded’ cases fulfilling 2010 
definite and borderline TFC were considered ‘mimics’ with confirmed alternative diagnosis, 
including hypertrophic cardiomyopathy (n=2), endomyocardial fibrosis (n=1), sarcoidosis 
(n=2), Brugada syndrome (n=1) and asymptomatic athlete’s heart (n=1).  Eight cases fulfilling 
1994 definite and borderline TFC were considered to have possible early ARVC; however, 
none of these cases had sufficient 2010 TFC to confirm a diagnosis at baseline or follow-up 
and were therefore excluded from the registry by the DP. 
 
 
Table 3.2.1. Summary of both TFC in all cases referred to the ARVC Registry 
Task Force Criteria  Cases referred to 









     Definite 
     Borderline 
     Possible 

















     Definite 
     Borderline 
     Possible  
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Table 3.2.2. Comparing the diagnostic yields of the 2010 versus 1994 TFC in the ‘DP    
                    included’ cohort 






2010 No criteria,  
n=0 (%) 
1994 Definite, n=47 (%) 
1994 Borderline, n=12 (%) 
1994 Possible, n=8 (%) 






















% DP included, n = 68 
 
Figure 10. Comparing the diagnostic yields of the 2010 versus 1994 TFC in the 'DP 
included' cohort in percentage. 
 
 
We further analysed the utility of the 2010 versus 1994 TFC according to mutation-status. A 
definite diagnosis confirmed by 2010 TFC was seen in all (100%) mutation-positive 
participants, and only in 72.1% of mutation-negative and 63.6% of mutation-unknown 
participants. The remaining mutation-negative and mutation-unknown participants fulfilled 
borderline criteria (Table 3.2.4). Comparatively, a definite diagnosis according to 1994 TFC 
was seen in 85.7% (12/14) of mutation-positive participants, with 14.3% (2/14) of mutation-
positive participants fulling only borderline criteria (Table 3.2.4 or Figure 11). No mutation-
positive participants were considered to have a possible or a no criteria diagnosis by either 









0 10 20 30 40 50 60 70 80 90 100
2010 Definite, n = 52
2010 Borderline, n = 16
2010 Possible, n = 0
2010 No criteria, n = 0
1994 Definite, n = 47 1994 Borderline, n = 12 1994 Possible, n = 8 1994 No criteria, n = 1
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Table 3.2.3. Comparing the diagnostic yields of the 2010 versus 1994 TFC in the mutation- 
                     positive cohort 






2010 No criteria, 
n=0 (%) 
1994 Definite, n=12 (%) 
1994 Borderline, n=2 (%) 
1994 Possible, n=0 (%) 




















% Mutation-positive, n = 14 
 
Figure 11. Comparing the diagnostic yields of the 2010 versus 1994 TFC in the 
mutation-positive cohort in percentage. 
 
 
When comparing the mean number of major and minor criteria according to mutation status 
(Table 3.2.4), we found a significant difference in the number of 2010 major criteria between 
mutation-positive and mutation-negative groups. A statistically significant difference was noted 
even with the exclusion of gene mutation as a criterion (2.50 ±0.855 versus 1.74 ±0.848, 
p=0.005).  A summary of the specific criteria according to mutation status is summarised in 











0 10 20 30 40 50 60 70 80 90 100
2010 Definite, n = 14
2010 Borderline, n = 0
2010 Possible, n = 0
2010 No criteria, n = 0
1994 Definite, n = 12 1994 Borderline, n = 2 1994 Possible, n = 0 1994 No criteria, n = 0
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Table 3.2.4. Summary of the diagnostic yield from each TFC according to mutation status 















Mean major criteria (±SD) 


















































Mean major criteria (±SD) 
(mutation included) 
Mean major criteria (±SD) 
(mutation excluded) 





























































SD = standard deviation 
*p-value represents the comparison between the diagnostic yield of each TFC in the mutation-positive (n=14) and 




Tables 3.2.5 and 3.2.6 describe the specific criteria fulfilled by participants in both ‘DP 
included’ (n=68) and ‘DP excluded’ (n=82) groups. When comparing specific criteria of the 
2010 versus 1994 TFC; there was notable variability in the yield of various major and minor 
criteria (illustrated in Figure 12 and 13).  The variations illustrated were attributed to:  
1) the inclusion of quantifiable criteria in the 2010 TFC for structural abnormalities (in 
both echocardiography and CMR) and tissue characterisation (EMB);  
2) the distinction between major and minor repolarisation and arrhythmia criteria; and  
3) the inclusion of molecular genetic results in the 2010 TFC.    





 #FFR = Fibrofatty replacement; EMB = Endomyocardial biopsy   
Table 3.2.5. 2010 Task Force criteria in all cases referred to the ARVC registry 





















Structural abnormalities  
   Structural major 
   Structural minor 
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   FFR# not quantified  
























































   Repolarisation major 
   Repolarisation minor 











































   Depolarisation major 
   Depolarisation minor 













































    Arrhythmia major 
































Family history  
   Family history major - excl. mutation  
   Family history major - incl. mutation 


















































EMB = endomyocardial biopsy 
Table 3.2.6. 1994 Task Force criteria in all cases referred to the ARVC registry 





















Structural abnormalities        
   Structural major 
   Structural minor  
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   Depolarisation major 
   Depolarisation minor 












































60 (88.2) 41 (87.2) 11 (91.7) 7 (87.5) 1 (100) 34 (41.5) 6 (66.7) 6 (37.5) 15 (46.9) 7 (28) 
Family history  
   Family history major 











































*FFR = fibrofatty replacement; EMB = endomyocardial biopsy 
 
  
Table 3.2.7. Summary of both Task Force criteria according to mutation status  













   Structural abnormalities 
Major criteria 
Minor criteria 
Imaging not done 
   Tissue characteristics   
Major criteria 
Minor criteria 
FFR* not quantified 
EMB not done 
   Repolarisation abnormalities 
Major criteria 
Minor criteria 
   Depolarisation abnormalities  
Major criteria 
Minor criteria 
   Arrhythmia  
Major criteria 
Minor criteria 














































































   Structural abnormalities 
Major criteria 
Minor criteria 
Imaging not done 
   Tissue characteristics   
Major criteria 
EMB not done 
   Repolarisation abnormalities 
Minor criteria 
   Depolarisation abnormalities   
Major criteria 
Minor criteria 
   Arrhythmia  
Minor criteria 
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Structural Tissue Repolarisation Depolarisation Arrythmia Family History








Structural Tissue Repolarisation Depolarisation Arrythmia Family History








Structural Tissue Repolarisation Depolarisation Arrythmia Family History








Structural Tissue Repolarisation Depolarisation Arrythmia Family History
% 'DP excluded' minor criteria, n=82
2010 1994
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Structural Tissue Repolarisation Depolarisation Arrythmia Family History








Structural Tissue Repolarisation Depolarisation Arrythmia Family History








Structural Tissue Repolarisation Depolarisation Arrythmia Family History








Structural Tissue Repolarisation Depolarisation Arrythmia Family History
% Mutation-negative minor criteria, n=43
2010 1994
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3.3       The outcome of diagnostic modalities using the 2010 TFC in cases  
      referred to the ARVC registry 
 
The TFC utilise information obtained from a spectrum of at least seven diagnostic modalities, 
excluding DNA analysis, to help make a diagnosis of ARVC. In the referred cohort (n=150) 
and using the 2010 TFC, there was no significant difference in the number of diagnostic 
modalities utilised in the workup of participants in either the ‘DP included’ or ‘DP excluded’ 
groups, with the exception for CMR (42.6% versus 63.4%, p=0.011) and echocardiography 
(86.8% versus 96.3%, p=0.031) (Table 3.3.1 and Figure 14). 
 
Table 3.3.1. Summary of diagnostic modalities performed using the 2010 TFC in cases 
referred to the ARVC Registry 
 Cases referred to 
ARVC registry, 
n=150 (%) 
‘DP included’,  
 
n=68 (%) 







































CMR = cardiovascular magnetic resonance; RVA = right ventricular angiography; SAECG= Signal-averaged 
electrocardiogram; EMB = endomyocardial biopsy. 



















Figure 14. Percentage of diagnostic modalities performed using the 2010 TFC in cases 












ARVC Registry, n=150 (%) DP included, n=68 (%) DP excluded, n=82 (%)
Echocardiogram CMR RVA ECG SAECG 24-hour Holter EMB
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We also analysed the number of diagnostic modalities performed according to mutation status 
and found no statistically significant differences between both the mutation-positive and 
mutation-negative groups (Table 3.3.2 and Figure 15).  
 
 
Table 3.3.2. Summary of diagnostic modalities performed using the 2010 TFC 














































CMR = cardiovascular magnetic resonance; RVA = right ventricular angiography; SAECG= Signal-averaged 
electrocardiogram; EMB = endomyocardial biopsy. 
*p-value represents the comparison between each diagnostic modality in mutation-positive (n=14), and mutation-
























Figure 15. Percentage of diagnostic modalities performed using the 2010 TFC 














Mutation-positive, n=14 (%) Mutation-negative, n=43 (%) Mutation-unknown, n=11 (%)
Echocardiogram CMR RVA ECG SAECG 24-hour Holter EMB
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3.4       Performance of diagnostic modalities using the 2010 versus 1994 TFC 
      at diagnosing mutation-positive definite probands 
 
We reported on the independent performance of frequently utilised diagnostic modalities in 
mutation-positive definite participants using the 2010 and 1994 TFC (Figure 16 and 17). 
Modalities fulfilling structural imaging and tissue characterisation were seen less frequently 
when using the stricter quantified 2010 TFC. Echocardiography, when comparing the 2010 
versus 1994 TFC, satisfied only half the number of positive criteria (23.1% versus 46.2%). A 
similar finding was appreciated when endomyocardial biopsy was compared (22.2% versus 
44.4%). Remarkably, only CMR provided a complete set of positive criteria (100%) using both 
TFC (p=0.021). Repolarisation abnormalities contributed positive diagnostic criteria in 85.7% 
of cases using the 2010 TFC, while depolarisation abnormalities including epsilon waves only 
provided positive criteria in 7.1% of cases when using either TFC.   
















  CMR = cardiovascular magnetic resonance; RVA = right ventricular angiography; EMB = endomyocardial biopsy. 
  *p-value represents the comparison of positive criteria contributed by each diagnostic modality in the mutation-positive cohort (n=14) using the 2010 and 1994 TFC.  
Table 3.3.3. Summary of positive criteria fulfilled by specific diagnostic modalities using both TFC according to mutation status 



























































































- 1 (9.1) 5 (45.5) 
p-value* 0.523 0.151 0.021 0.066 0.617 0.675 0.963 0.547 0.210 - 0.834 0.007 
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Figure 16. Percentage of positive criteria fulfilled by specific diagnostic modalities 








Figure 17. Percentage of positive criteria fulfilled by specific diagnostic modalities 

































Mutation-positive, n=14 (%) Mutation-negative, n=43 (%) Mutation-unknown, n=11 (%)
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Chapter 4 - Discussion  
 
In this study, we report a comparison between the original 1994 and revised 2010 TFC in 
diagnosing ARVC, and the utility of the criteria in identifying mutation-positive probands. One 
hundred and fifty participants were evaluated by the DP; 68 were diagnosed with ARVC and 
included into the ARVC registry (‘DP included’) within the IMHOTEP study, and 82 participants 
were excluded (‘DP excluded’) with alternative diagnosis or insufficient criteria. There were no 
differences in gender, ethnicity or symptoms at presentation between the ‘DP included’ and 
‘DP excluded’ groups with the exception of presyncope. Importantly, both groups were 
investigated similarly with one exception; imaging modalities such as CMR and 
echocardiography were more frequently performed in the ‘DP excluded’ group compared to 
the ‘DP included’ group. These observations infer that all cases in the ‘DP excluded’ group 
were adequately investigated and were not excluded due to incomplete clinical work-up. 
Furthermore, an alternative diagnosis was made in the majority of excluded cases, and no 
pathogenic genetic variants were found in the participants screened. The mean age of 
participants referred (n=150) was 35.9 ± 14.9 years, with no substantial differences found 
between the ‘DP included’ and ‘DP excluded’ groups. A statistically significant difference was 
noted in the mean age of onset between mutation-positive and mutation-negative probands, 
suggesting the earlier onset of ARVC in those with a pathogenic genetic variant. Sustained 
VT at presentation occurred in more than half of those with ARVC (‘DP included’) and less 
than a third of those in the ‘DP excluded’ cohort. Mutation-positive participants were more 
frequently found to present with VT compared to those in the mutation-negative group. Our 
study found young Caucasian males presenting with sustained VT were more likely to have a 
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International comparison 
Large trans-Atlantic studies have described mutation-positive participants as earlier 
presenters of ARVC (mean age of onset, 34 ±14 years) when compared to mutation-negative 
individuals.57 In our study, representing cases from SSA, mutation-positive participants were 
found to present significantly younger (mean age of onset, 28.5 ±13.96 years) than those 
described internationally. Our study also identified a greater predominance of sustained VT at 
presentation in our mutation-positive group compared to the global north (78.6% versus 
52.0%).57 Participants in our study contributed a similar number of positive 2010 TFC as 
described in international cohorts.57 The overall number of diagnostic modalities responsible 
for fulfilling imaging criteria were also found to be similar, however, our cohort had a higher 
trend towards invasive modalities.57 These findings are in keeping with investigative strategies 
prior to the arrival of CMR in SSA. After analysing each diagnostic modality’s ability at 
contributing major 2010 TFC in mutation-positive definite participants, we found the addition 
of CMR statistically significant and a preferred imaging tool when screening for ARVC. 
 
Improvement of diagnosis  
Our study emphasised the importance of re-classifying all participants previously referred and 
classified using outdated criteria (i.e. 1994), with updated (i.e. 2010) TFC in a traditional ARVC 
registry. Of the 52 participants classified as 2010 TFC definite in our ‘DP included’ cohort, only 
83% comprised of 1994 definite cases, while 15% represented previously classified 1994 
borderline cases. Of the 16 participants classified with a 2010 TFC borderline diagnosis (‘DP 
included’ cohort), a quarter originated from cases previously diagnosed as 1994 definite, while 
only 25% remained unchanged with a 1994 borderline diagnosis. A significant majority of the 
2010 borderline cases originated from cases previously classified as 1994 possible, and 
interestingly a further 6% arose from cases that occupied no criteria according to the 1994 
TFC. The most striking reasons for diagnostic change were found in 3 main categories: 1) the 
appreciation of precordial T-wave inversion as major criteria; 2) morphometric analysis of 
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myocardial biopsies quantifying fibro-fatty involvement in keeping with ARVC pathology, and; 
3) the recognition of VT with a superior axis as a major criterion of ARVC. The overall 
diagnostic yield of the 2010 versus 1994 TFC revealed more participants with a definite 
diagnosis, and less featuring in possible and no criteria categories. A considerable upgrade 
(66.7%) in diagnosis from 1994 borderline to 2010 definite was observed, with an 8.5% 
downgrade from 1994 definite to 2010 borderline. One of the main reasons for a downgrade 
in diagnosis was seen after the removal of wide QRS complexes as a 1994 TF major 
depolarisation criterion. A further 12.5% of cases previously classified as 1994 possible were 
re-classified as having a 2010 definite diagnosis. Changes in diagnostic classification have 
significant implications when risk stratifying patients for future management and were mainly 
seen in individuals recruited prior to 2010. Our ‘DP excluded’ cohort revealed fewer 
participants as definite (4.9% versus 11%), and borderline ARVC (3.75% versus 19.5%), and 
more cases as no criteria (61% versus 30.5%), when using the 2010 versus 1994 TFC. The 
utility of the 2010 and 1994 TFC strictly according to mutation-positive status found a higher 
yield for definite ARVC, and led to a complete change in diagnosis from 1994 borderline to 
2010 definite.   
 
Application of Task Force criteria  
Our study found the total number of major clinical criteria using the 2010 TFC as a predictive 
marker in identifying mutation-positive individuals with ARVC even with the exclusion of 
genotype as a criterion (2.50 ±0.855 versus 1.74 ±0.848, p=0.005). We identified similar 
patterns in the distribution of major criteria across the ‘DP included’ and mutation-positive 
cohorts when using both the 2010 and 1994 TFC. In keeping with international literature, we 
found a greater fulfilment of 2010 TF repolarisation criteria, with fewer fulfilment of 
depolarisation and tissue characterisation criteria. These findings beautifully demonstrate the 
shift in diagnostic weight between each TFC with the 2010 TFC placing more emphasis on 
repolarisation abnormalities over previously favoured depolarisation and histological 
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abnormalities. The quantification driven 2010 TFC was further highlighted when fewer tissue 
characterisation and structural imaging criteria were fulfilled in the ‘DP excluded’ group, 
emphasising the improved diagnostic accuracy of 2010 TFC at identifying and excluding 
mimics. The 1994 TFC contributed an overall greater amount of structural imaging criteria, a 
common late finding in ARVC. Comparatively, the 2010 TFC contributed a higher amount of 
repolarisation abnormalities, an established sensitive marker for early disease ARVC. Our 
study successfully compared the utility of the original 1994 TFC to the revised 2010 TFC at 
diagnosing mutation-positive probands with ARVC and demonstrated a new shift in clinical 




Our study found that mutation-positive probands were found to be younger, more likely to 
present with sustained VT, fulfilled a significantly larger number of major 2010 TFC than 
mutation-negative probands, and that the 2010 TFC for structural and repolarisation 
abnormalities were more useful in diagnosing ARVC compared to 1994 TFC. We found a 
significant evolution in classification between both TFC, suggesting that re-classification of 




Our study was limited by its retrospective design. In addition, ARVC is a rare disease requiring 
sophisticated investigations and clinical expertise that are not readily available at all levels of 
care in sub-Saharan Africa. As a consequence, the number of participants with ARVC in this 
study were relatively small, particularly in the mutation-positive group. Due to the small number 
of mutation-positive participants and the fact that mutation-negative individuals may habour a 
undiscovered pathogenic variant, the statistical analysis should be interpreted with some 
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caution. Furthermore, the majority of participants were recruited at a tertiary centre with 
notable historical referral bias; therefore, it is likely that this cohort represents a more severe 
spectrum of disease and not truly representative of the population. As this data was collected 
for the purposes of a registry, each participant was not investigated with all diagnostic 
modalities, which is a reflection of choices made in daily clinical practise in a resource-
restricted environment. As ARVC cannot be diagnosed by a single diagnostic modality and 
disease expression varies between individual patients, there was a large variation in clinical 
criteria used to establish a diagnosis of ARVC in this cohort. These factors have limited our 
ability to make more precise deductions about the sensitivity and specificity both the TFC and 
individual diagnostic modalities have, therefore, have not been included in the analysis. 
Despite these limitations, this study has highlighted important insights into the utility of the 
diagnostic criteria in our local context. Our study has generated opportunities for future 
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Appendix 1: 1994 ARVC Task Force criteria - Case Report Form 
 
Unique ID: _____________      SEX: _ 
__ 
GLOBAL AND / OR REGIONAL DYSFUNCTION AND STRUCTURAL ALTERATIONS  
MAJOR  
o Severe dilatation and reduction of right ventricular ejection fraction with no (or only mild) LV 
impairment 
o Localised right ventricular aneurysms (akinetic or dyskinetic areas with diastolic bulging) 
o Severe segmental dilatation of the right ventricle 
 
MINOR  
o Mild global right ventricular dilatation and/or ejection fraction reduction with normal left 
ventricle 
o Mild segmental dilatation of the right ventricle 
o Regional right ventricular hypokinesia 
 
TISSUE CHARACTERISATION OF WALLS  
MAJOR  
o Fibrofatty replacement of myocardium on endomyocardial biopsy  
REPOLARISATION ABNORMALITIES  
MINOR  
o Inverted T waves in right precordial leads (V2 and V3) (people aged more than 12 years; in 
absence of right bundle branch block) 
 
 
DEPOLARISATION / CONDUCTION ABNORMALITIES  
MAJOR  




o Late potentials (signal averaged ECG)  
ARRHYTHMIAS  
MINOR  
o Left bundle branch block type ventricular tachycardia (sustained and non-sustained) (ECG, 
Holter, exercise testing). 
o Frequent ventricular extra systoles (more than 1000/24 h) (Holter) 
 
FAMILY HISTORY  
MAJOR  
o Familial disease confirmed at necropsy or surgery  
MINOR  
o Familial history of premature sudden death (<35 year) due to suspected right ventricular 
dysplasia. 
o Familial history (clinical diagnosis based on present criteria 
 
 
Diagnosis Major Minor 
   
 
Definite Borderline Possible No Criteria 
2 major; or 1 major plus 1 minor; or 1 major; or 0 major; or 
1 major plus 2 minor; or 3 minor criteria 2 minor criteria 0 minor criteria 
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Appendix 2: 2010 ARVC Task Force Criteria - Case Report Form 
 
Unique ID: ______________      SEX: ____ 
 
GLOBAL OR REGIONAL DYSFUNCTION AND STRUCTURAL ALTERATIONS  
MAJOR  
By 2D echo: 
Regional RV akinesia, dyskinesia, or aneurysm and 1 of the following: 
o PLAX RVOT ≥ 32 mm (corrected for body size [PLAX/BSA] ≥ 19 mm/m2) 
o PSAX RVOT ≥ 36 mm (corrected for body size [PSAX/BSA] ≥ 21 mm/m2) 
o Fractional area change ≤ 33% 
 
By MRI: 
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following: 
o Ratio of RV end-diastolic volume to BSA ≥ 110 mL/m2(male) or ≥ 100 mL/m2(female) 
o RV ejection fraction ≤ 40% 
 
By RV angiography: 
o Regional RV akinesia, dyskinesia, or aneurysm 
 
MINOR  
By 2D echo: 
Regional RV akinesia or dyskinesia and 1 of the following: 
o PLAX RVOT ≥ 29 to < 32 mm (corrected for body size [PLAX/BSA] ≥ 16 to < 19 mm/m2) 
o PSAX RVOT ≥ 32 to < 36 mm (corrected for body size [PSAX/BSA] ≥ 18 to < 21 mm/m2) 
o Fractional area change > 33% to ≤ 40% 
 
By MRI: 
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following:  
o Ratio of RV end-diastolic volume to BSA ≥ 100 to < 110 mL/m2 (male) or ≥ 90 to < 100 mL/m2 
(female) 
o RV ejection fraction > 40% to ≤ 45% 
 
TISSUE CHARACTERISATION OF WALL  
MAJOR  
o Residual myocytes < 60% by morphometric analysis (or < 50% if estimated), with fibrous 
replacement of the RV free wall myocardium in ≥ 1 sample, with or without fatty replacement of 
tissue on endomyocardial biopsy 
 
MINOR  
o Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with 
fibrous replacement of the RV free wall myocardium in ≥ 1 sample, with or without fatty 
replacement of tissue on endomyocardial biopsy 
 
REPOLARISATION ABNORMALITIES  
MAJOR  
o Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in individuals > 14 years 
of age (in the absence of complete right bundle-branch block QRS ≥ 120 ms) 
 
MINOR  
o Inverted T waves in leads V1 and V2 in individuals > 14 years of age (in the absence of 
complete right bundle-branch block) or in V4, V5, or V6 
 
o Inverted T waves in leads V1, V2, V3, and V4 in individuals > 14 years of age in the presence of 
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DEPOLARISATION / CONDUCTION ABNORMALITIES  
MAJOR  
o Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the 
T wave) in the right precordial leads (V1 to V3) 
 
MINOR  
o Late potentials by SAECG in ≥ 1 of 3 parameters in the absence of a QRS duration of ≥ 110 ms 
on the standard ECG 
• Filtered QRS duration (fQRS) ≥ 114 ms 
• Duration of terminal QRS < 40 µV (low-amplitude signal duration) ≥ 38 ms 
• Root-mean-square voltage of terminal 40 ms ≤ 20 µV 
o or Terminal activation duration of QRS ≥ 55 ms measured from the nadir of the S wave to the end 




o Non-sustained or sustained ventricular tachycardia of left bundle-branch morphology with 
superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL) 
 
MINOR  
o Non-sustained or sustained ventricular tachycardia of RV outflow configuration, left bundle-
branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in 
lead aVL) or of unknown axis 
o > 500 ventricular extra systoles per 24 hours (Holter) 
 
 
FAMILY HISTORY  
MAJOR  
o ARVC confirmed in a first-degree relative who meets current Task Force criteria 
o ARVC confirmed pathologically at autopsy or surgery in a first-degree relative 
o Identification of a pathogenic mutation† categorised as associated or probably associated with 
ARVC/D in the patient under evaluation 
 
MINOR  
o History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine 
whether the family member meets current Task Force criteria 
o Premature sudden death (< 35 years of age) due to suspected ARVC/D in a first-degree relative 





Definite Borderline Possible No Criteria 
2 major; or 1 major plus 1 minor; or 1 major; or 0 major; or 
1 major plus 2 minor; or 3 minor criteria 2 minor criteria 0 minor criteria 
4 minor criteria  
Diagnosis Major Minor 
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Appendix 3: Human Research Ethics Approval - HREC REF 766/2014 
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